Recursion Pharmaceuticals, Inc. (RXRX) tiene un P/E histórico negativo de -2.7, lo que significa que la empresa actualmente no es rentable en base a los últimos doce meses (TTM). El rendimiento de ganancias histórico es -37.09%.
Criterios demostrados por esta página:
Puntuación General SharesGrow: 43/100 con 1/7 criterios aprobados.
| Year | P/E (TTM) | Ratio PEG | Ratio P/B | Ratio P/S | Rendimiento por Dividendo |
|---|---|---|---|---|---|
| 2019 | -47.7 | 0.00 | -24.02 | 1,744.15 | - |
| 2020 | -34.3 | -0.84 | -14.47 | 874.38 | - |
| 2021 | -15.6 | -0.16 | 5.37 | 291.68 | - |
| 2022 | -5.7 | -0.19 | 2.79 | 34.11 | - |
| 2023 | -6.2 | -0.39 | 4.42 | 46.71 | - |
| 2024 | -4.0 | -0.57 | 1.79 | 31.50 | - |
| 2025 | -2.8 | 0.19 | 1.62 | 24.50 | - |
| Year | EPS (Diluido) | Ingresos | Ingreso Neto | Margen Neto |
|---|---|---|---|---|
| 2019 | $-0.37 | $1.71M | $-62.53M | -3654.3% |
| 2020 | $-0.52 | $3.41M | $-87.88M | -2574.9% |
| 2021 | $-1.05 | $10M | $-178.07M | -1780.7% |
| 2022 | $-1.36 | $39.68M | $-239.42M | -603.4% |
| 2023 | $-1.58 | $44.58M | $-328.07M | -736% |
| 2024 | $-1.69 | $58.84M | $-463.66M | -788% |
| 2025 | $-1.44 | $74.68M | $-644.76M | -863.4% |
| Year | EPS (Prom.) | Rango EPS | Ingresos (Prom.) | Rango de Ingresos | Analistas |
|---|---|---|---|---|---|
| 2026 | $-0.99 | $-1.22 – $-0.67 | $82.08M | $65M – $100.31M | 5 |
| 2027 | $-0.87 | $-1.01 – $-0.67 | $149.82M | $80.48M – $334.45M | 6 |
| 2028 | $-0.45 | $-0.95 – $-0.24 | $441.07M | $441.07M – $441.07M | 3 |
| 2029 | $-0.94 | $-2.00 – $-0.51 | $247.5M | $159.53M – $462.41M | 4 |
